You are here: Industry Insights > Absci

News List

Absci and Merck collaborate to develop new enzymes pharmaceutical-business-review
January 10, 2022
drug and target discovery company Absci has signed a research collaboration with Merck to produce new enzymes.
Absci Enters Research Collaboration with Merck contractpharma
January 07, 2022
Will deploy its Bionic Protein non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications.
Absci Strengthens Executive Leadership Team firstwordpharma
July 08, 2021
Absci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced two strategic hires joining its executive team: Nikhil Goel as Chief Business Officer and Dr. Sarah Korman as General Counsel.
AbSci Acquires Cell Therapy Company Totient contractpharma
June 18, 2021
Combination of Totient technology with AbSci's platform provides framework and data to enable in silico targeted drug design.
Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci prnasia
June 16, 2021
Viva Biotech declared today that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics.
AbSci Establishes New Collaboration with Sanofi pharmafocusasia
January 11, 2019
AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced a collaboration with Sanofi.....